"Biogen recently got hammered on 'bad' news that wasn't actually so bad. BIIB and partner Elan (NYSE: ELN) reported that two MS patients, out of 31,800 currently receiving Tysabri, developed a rare brain malady called PML.
"It's important to note, here, that the two companies had predicted that one in 1000 cases could develop PML and the FDA let the drug come to market with this understanding with a strong set of patient warnings and physician follow up.
"Tysabri has succeeded in the marketplace because it is a superior treatment for MS -- and the patients who use it agree, despite its high cost of $30,000 per year.
"The company didn't comment, but I expect only a very small drop off in market acceptance for Tysabri and when it becomes apparent the drug is still desired by patients and doctors, the stock should rebound significantly.
"BIIB is still targeting 100,000 patients by 2010 and that would translate into $1 billion per quarter in sales.
"The two cases of PML cut the stock by almost 30% -- and that's ridiculous. It's simply too big a move for a cash-rich, risk-free company with several major drugs -- especially Rituxan which is taking more market share every quarter.
"Biogen Idec also has the ability to add new products through licensing or direct acquisition, and I expect it to do so in the coming quarters.
"This temporary downturn is a godsend for investors! BIIB is now selling well below the valuations of other large-cap, double-digit biotech growers. Take advantage of this mistake before the Street wakes up."
"I’m now taking a very aggressive stance," says Roger Conrad; in his Utility Forecaster, he sees the "underpinnings of a powerful rebound." Here, he eyes Chevron (NYSE: CVX).
"The markets are trying to stabilize, but the crisis continues," say Mary Anne and Pamela Aden. In their industry leading The Aden Forecast, they update their favorite top resource ideas.
Jack Adamo has been a bull on U.S. Bancorp (NYSE: USB) and is now recommending doubling the position that he holds in his model portfolio. Here's the latest from Insiders Plus.
"Investors should keep a defensive posture," says Richard Moroney. However, the editor of the blue chip Dow Theory Forecasts see opportunity in two drug stocks just added to his buy list.
After locking in 30%+ gains on his recent trading positions in ETFs that went short, Doug Fabian has now switched to a long ETF position in gold. Here's the latest from The ETF Trader.
"When investing in Asia, most investors think of growth; but the region has its share of income stocks," says Walter Frank. In Moneyletter, he profiles two Matthews International funds.
A new book from The Oxford Club's Alexander Green -- The Gone Fishin' Portfolio -- provides investors with an exceptional all-weather approach to building long-term wealth.
His simple to follow and time-tested asset allocation strategy eliminates the worries of market volatility, market timing and the inherent risks of emotional decision-making in your investing process.
Mark Skousen's latest book, “EconoPower: How a New Generation of Economists is Transforming the World” (Wiley & Sons), is available for $16.47 (plus shipping) from Amazon.com (retail price is $24.95).
Included is a discussion of the new field of behavioral finance, with economists as Richard Thaler, Robert Shiller, and Jeremy Siegel.
Sy Harding, editor of Street Smart Report, has just published Beat the Market the Easy Way -- an in-depth review of seasonal market patterns and their application to long-term timing.
For 40 years, Dick Davis has been noted for his straight talk and common sense. In The Dick Davis Dividend, he shares a lifetime of insights on investing.
"If you want to buy a great company dirt cheap, think 
"I’m now taking a very aggressive stance," says 
"The markets are trying to stabilize, but the crisis continues," say 
"Investors should keep a defensive posture," says 
After locking in 30%+ gains on his recent trading positions in ETFs that went short, 
"We have made only one long-term investment recently: 
"When investing in Asia, most investors think of growth; but the region has its share of income stocks," says 
"Even in tough times, 
"
